FDA Approves Periostat Generics, But Launch Could Hinge On Patent Case
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approves three ANDAs for Periostat tablets and one for the capsule formulation. In a patent infringement lawsuit, Periostat marketer CollaGenex is requesting that a federal court preliminarily enjoin launches by Ivax and CorePharma.